Severe Sepsis and Septic Shock - Epidemiology Forecast to 2030
Summary Severe sepsis and septic shock are life-threatening conditions with a very high mortality rate.Severe sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection criteria.
Septic shock is defined as a state of acute circulatory failure characterized by persistent arterial hypotension that cannot be successfully rescued by fluid resuscitation criteria. A constellation of clinical, laboratory, physiologic, and microbiologic data is required for the diagnosis of severe sepsis and septic shock.
Epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, taking into account the significant relationship between age and Severe sepsisEpidemiologists applied country-specific incidence rates of severe sepsis and septic shock wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.
The following data describes epidemiology of severe sepsis and septic shock cases.In 2020, the 7MM had 2,344,143 diagnosed incident cases of severe sepsis.
This is expected to increase to 2,794,568 diagnosed incident cases by 2030, at an Annual Growth Rate (AGR) of 1.92%. In the 7MM, the diagnosed incident cases of septic shock will increase from 559,513 cases in 2020 to 664,991 cases in 2030, at an AGR of 1.89%. This increase is partly attributed to the moderately rising trend in incidence in the 7MM, combined with underlying demographic changes in the respective markets. The early diagnosis and development of more effective therapies would improve survival from severe sepsis and septic shock.
Scope - Severe Sepsis and Septic Shock Epidemiology Report provides an overview of the risk factors and global trends of severe sepsis and septic shock in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 7MM: diagnosed incident cases of severe sepsis, and septic shock. Diagnosed incident cases of severe sepsis and septic shock are further segmented by causative agents and organ dysfunction. Additionally, epidemiologists provide a forecast for the in-hospital mortality cases of severe sepsis and septic shock.
- The Severe Sepsis and Septic Shock Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy The Severe Sepsis and Septic Shock epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global severe sepsis and septic shock market.
- Quantify patient populations in the global severe sepsis and septic shock market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the causative agents that present the best opportunities for therapeutics in each of the markets covered.
- Understand magnitude of organ dysfunction in severe sepsis and septic shock in these markets.
Our reports have been used by over 10K customers, including:
Melanoma - Epidemiology Forecast to 2029 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
Stretch goals: Rising disposable incomes and an aging population will drive revenue growth Abstract Physical Therapists in the US Over the five years to 2019, the role of physical therapy in promoting health and wellness has increased, benefiting this industry. As the number of individuals aged 50 and...
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.The most common clinical scenario for RSV is an...
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
Melanoma - Global Drug Forecast and Market Analysis to 2029 Summary Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
17 pages •
By Euromonitor International
• Dec 2020
Positive net migration will be the main driver of UK population growth in 2019-2040. Ageing will be a key demographic trend over this time, transforming consumer trends and putting further pressure on state resources. Immigrants will make up over a tenth of the UK population by 2040, with those from Poland and India continuing to make up the...
17 pages •
By Euromonitor International
• Nov 2020
After peaking in 2024, depopulation will occur in Germany up to 2040 as falling net migration rates are no longer able to mitigate increasingly negative natural change. As birth rates drop and longevity climbs, ageing will accelerate transforming consumer trends and putting additional pressure on state resources. Urbanisation will continue...
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029 Summary Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
Opportunity Analyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche’s Esbriet and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval...
Commercial Real Estate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.